NEW YORK (GenomeWeb) – Aelan Cell Technologies announced today that it has acquired a worldwide license to a US patent from the Buck Institute for Research on Aging related to an undisclosed epigenetic biomarker for Alzheimer's disease.

According to the company, the patent is based on work conducted by Aelan Founder, President, and CEO Victoria Lunyak while she was a researcher at the Buck Institute, and covers a biomarker associated with DNA damage, cellular senescence, and aging.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.